Российское диализное общество

Просмотр статьи

<< Вернуться к списку статей журнала

Том 21 №2 2019 год - Нефрология и диализ

Клинические практические рекомендации KDIGO 2018 по профилактике, диагностике, оценке и лечению гепатита С при хронической болезни почек


DOI: 10.28996/2618-9801-2019-2-105-190

Аннотация: Kidney International Supplements (2018) 8, 91-165 © 2018 KDIGO Перевод с английского Е.С. Камышовой и Е.В. Захаровой под общей редакцией Е.В. Захаровой Перевод выполнен по инициативе Российского Диализного Общества и одобрен KDIGO Translation to Russian by E.S. Kamyshova and E.V. Zakharova, ed. E.V. Zakharova Translation was initiated by Russian Dialysis Society and approved by KDIGO Все права принадлежат KDIGO Воспроизведение возможно только с разрешения РДО и KDIGO Предисловие к переводу на русский язык Клинических практических рекомендаций KDIGO 2018 по профилактике, диагностике, оценке и лечению гепатита С при хронической болезни почек Глубокоуважаемые коллеги! В этом номере журнала Нефрология и Диализ мы продолжаем серию публикаций переводов на русский язык Клинических Практических Рекомендаций KDIGO и предлагаем вашему вниманию перевод Рекомендаций по профилактике, диагностике, оценке и лечению гепатита С при хронической болезни почек. Как и предыдущие переводы, опубликованные в журнале Нефрология и Диализ, данный перевод осуществлен по инициативе Российского Диализного Общества с разрешения KDIGO. Руководство РДО и редколлегия журнала Нефрология и Диализ надеются, что публикуемый материал будет полезен вам в вашей работе. На сайте журнала Нефрология и Диализ и на сайте KDIGO вы можете также найти осуществленные по инициативе РДО переводы на русский язык Клинических Практических Рекомендаций KDIGO по МКН-ХБП, ОПП, Анемии у больных с ХБП, Гломерулонефритам, Ведению дислипидемии у пациентов с ХБП и Диагностике и Лечению Хронической Болезни Почек. Мы планируем и в дальнейшем знакомить вас с материалами KDIGO, с новостями от KDIGO вы можете ознакомиться на специальной страничке в конце каждого выпуска нашего журнала. С наилучшими пожеланиям от имени KDIGO и РДО, заместитель главного редактора журнала «Нефрология и Диализ» Е.В. Захарова Клинические практические рекомендации KDIGO 2018 по профилактике, диагностике, обследованию и лечению гепатита С при хронической болезни почек представляют собой полностью обновленный вариант предыдущих рекомендаций, опубликованных в 2008 г. Данное руководство предназначено для оказания помощи в практическим врачам при лечении пациентов, инфицированных вирусом гепатита С (ВГС) и страдающих хронической болезнью почек (ХБП), включая и пациентов, получающих лечение хроническим диализом и реципиентов почечного трансплантата. Основные специфические вопросы, освещаемые в новых рекомендациях, включают выявление и оценку ВГС у пациентов с ХБП, лечение ВГС-инфекции у пациентов с ХБП, лечение инфицированных ВГС пациентов до и после трансплантации почки, профилактику передачи ВГС в отделениях гемодиализа, а также диагностику и лечение заболеваний почек, ассоциированных с ВГС. Разработка данных рекомендаций проводилась в строгом соответствии с процессом рассмотрения и оценки доказательств. Подходы к лечению и положения рекомендаций основаны на систематическом обзоре соответствующих исследований, а оценка качества доказательств и силы рекомендаций проводилась в соответствии с системой оценки, разработки и изучения рекомендаций GRADE (Grading of Recommendations Assessment, Development and Evaluation). Обсуждаются случаи ограничения доказательности результатов, а также представлены рекомендации по будущим исследованиям.

Весь текст



Ключевые слова: хроническая болезнь почек, криоглобулинемия, диализ, препараты прямого противовирусного действия, гломерулярные заболевания, гемодиализ, вирус гепатита С, контроль над инфекциями, рекомендации, KDIGO, трансплантация почки, печеночные пробы, внутрибольничная передача инфекции, скрининг, систематический обзор

Список литературы:
  1. Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017;389:403-476.
  2. The Lancet Gastroenterology Hepatology. Access to HCV treatments: hurdles not barriers. Lancet Gastroenterol Hepatol. 2017;2:1.
  3. Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection [e-pub ahead of print]. Hepatology. https://doi.org/10.1002/hep.30046. Accessed July 25, 2018.
  4. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July 2018. Available at: http://www.who.int/hepatitis/publications/hepatitis-cguidelines- 2018/en/. Accessed July 27, 2018.
  5. Bergman S, Accortt N, Turner A, et al. Hepatitis C infection is acquired pre- ESRD. Am J Kidney Dis. 2005;45:684-689.
  6. Iwasa Y, Otsubo S, Sugi O, et al. Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan. Clin Exp Nephrol. 2008;12:53-57.
  7. Fabrizi F, Verdesca S, Messa P, et al. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and metaanalysis. Dig Dis Sci. 2015;60:3801-3813.
  8. Crook ED, Penumalee S, Gavini B, et al. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005;28:2187-2191.
  9. Noureddine LA, Usman SA, Yu Z, et al. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol. 2010;32:311-316.
  10. Wyatt CM, Malvestutto C, Coca SG, et al. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and metaanalysis. AIDS. 2008;22:1799-1807.
  11. Easterbrook PJ. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65:S46-S66.
  12. Kamili S, Drobeniuc J, Araujo AC, et al. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55 Suppl 1:S43-S48.
  13. Cresswell FV, Fisher M, Hughes DJ, et al. Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. Clin Infect Dis. 2015;60:263-266.
  14. Hu KQ, Cui W. A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One-step diagnosis of viremic hepatitis C virus infection. Hepatology. 2016;64:415-424.
  15. Miedouge M, Saune K, Kamar N, et al. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol. 2010;48:18-21.
  16. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335-2342.
  17. Saune K, Kamar N, Miedouge M, et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant. 2011;26:2309-2316.
  18. Hmaied F, Ben Mamou M, Saune-Sandres K, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol. 2006;78:185-191.
  19. Izopet J, Sandres-Saune K, Kamar N, et al. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol. 2005;77:70-76.
  20. Mbaeyi C, Thompson ND. Hepatitis C virus screening and management of seroconversions in hemodialysis facilities. Semin Dial. 2013;26:439-446.
  21. Nguyen DB, Gutowski J, Ghiselli M, et al. A large outbreak of hepatitis C virus infections in a hemodialysis clinic. Infect Control Hosp Epidemiol. 2016;37:125-133.
  22. Savey A, Simon F, Izopet J, et al. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol. 2005;26:752-760.
  23. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1-43.
  24. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.
  25. Barril G, Bartolome J, Sanz P, et al. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels. J Med Virol. 2010;82:763-767.
  26. Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65:S33-S45.
  27. Centers for Disease Control and Prevention. Hepatitis C, Acute 2016: Case Definition. Available at: https://wwwn.cdc.gov/nndss/conditions/hepatitisc-acute/case-definition/2016/. Accessed July 27, 2018.
  28. Centers for Disease Control and Prevention Health Alert Network. CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C transmission in patients undergoing hemodialysis. Available at: https://emergency.cdc.gov/han/han00386.asp. Accessed July 27, 2018.
  29. Allander T, Medin C, Jacobson SH, et al. Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol. 1994;43:415-419.
  30. Hmaied F, Ben Mamou M, Dubois M, et al. Determining the source of nosocomial transmission in hemodialysis units in Tunisia by sequencing NS5B and E2 sequences of HCV. J Med Virol. 2007;79:1089-1094.
  31. Izopet J, Pasquier C, Sandres K, et al. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol. 1999;58:139-144.
  32. Kokubo S, Horii T, Yonekawa O, et al. A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat. 2002;9:450-454.
  33. Saab S, Martin P, Brezina M, et al. Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis. 2001;37:308-315.
  34. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008:S1-S99.
  35. Liu CH, Liang CC, Huang KW, et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin J Am Soc Nephrol. 2011;6:1057-1065.
  36. Jadoul M, Horsmans Y. Impact of liver fibrosis staging in hepatitis C virus (HCV) patients with kidney failure. Nephrol Dial Transplant. 2014;29:1108-1110.
  37. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-S155.
  38. Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol. 2006;37:1519-1526.
  39. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-185.
  40. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310-335.
  41. de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743-752.
  42. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461-511.
  43. Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5:528-540.
  44. Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3:3-14.
  45. Goodkin D, Bieber B, Jadoul M, et al. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12:287-297.
  46. Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96-e138.
  47. Asrani SK, Buchanan P, Pinsky B, et al. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol. 2010;8:79-84.
  48. Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011;57:396-402.
  49. Chen YC, Lin HY, Li CY, et al. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int. 2014;85:1200-1207.
  50. Hofmann JN, Torner A, Chow WH, et al. Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. Eur J Cancer Prev. 2011;20:326-330.
  51. Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9:e100790.
  52. Moe SM, Pampalone AJ, Ofner S, et al. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis. 2008;51:885-892.
  53. Molnar MZ, Alhourani HM, Wall BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:1495-1502.
  54. Su FH, Su CT, Chang SN, et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis. 2012;60:553-560.
  55. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271-1276.
  56. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1-150.
  57. Dalrymple LS, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2:715-721.
  58. Lucas GM, Jing Y, Sulkowski M, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis. 2013;208:1240-1249.
  59. Park H, Chen C, Wang W, et al. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD [e-pub ahead of print]. Hepatology. https://doi.org/10.1002/hep.29505.
  60. Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol. 2000;11:690-699.
  61. Ble M, Aguilera V, Rubin A, et al. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl. 2014;20:25-34.
  62. Norton BL, Park L, McGrath LJ, et al. Health care utilization in HIVinfected patients: assessing the burden of hepatitis C virus coinfection. AIDS Patient Care STDS. 2012;26:541-545.
  63. Fabrizi F, Dixit V, Martin P, et al. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: Systematic review and metaanalysis. J Med Virol. 2016;88:487-497.
  64. Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369-378.
  65. Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005;67:285-290.
  66. Tsui JI, Vittinghoff E, Shlipak MG, et al. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2006;17:1168-1174.
  67. Petta S, Adinolfi LE, Fracanzani AL, et al. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018;69:18-24.
  68. Rogal SS, Yan P, Rimland D, et al. Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. Dig Dis Sci. 2016;61:930-936.
  69. Tsui J, Vittinghoff E, Anastos K, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women’s Interagency HIV Study. Am J Kidney Dis. 2009;54:43-50.
  70. Hsu CS, Kao JH, Chao YC, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38:415-423.
  71. van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016;65:S95-S108.
  72. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIVand Hepatitis C virus. Clin Infect Dis. 2012;55:728-736.
  73. Arase Y, Suzuki F, Kawamura Y, et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res. 2011;41:946-954.
  74. Chen YC, Hwang SJ, Li CY, et al. A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease. Medicine (Baltimore). 2015;94:e1334.
  75. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495-503.
  76. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293-1302.
  77. Leone S, Prosperi M, Costarelli S, et al. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCVcoinfected patients who achieved sustained virological response. Eur J Clin Microbiol Infect Dis. 2016;35:1511-1520.
  78. Feng B, Eknoyan G, Guo ZS, et al. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant. 2012;27:640-646.
  79. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004;19:715-727.
  80. Tung J, Carlisle E, Smieja M, et al. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis. 2010;56:713-719.
  81. Fabrizi F, Martin P, Messa P. Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs. 2015;38:625-631.
  82. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-29.
  83. Simmons B, Saleem J, Hill A, et al. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62:683-694.
  84. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. Guidance for industry. 2017. Available at: https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf. Accessed March 23, 2018.
  85. Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and metaanalysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730-740.
  86. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637-648.
  87. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed June 12, 2018.
  88. Gamal N, Andreone P. Grazoprevir/elbasvir fixed-dose combination for hepatitis C. Drugs Today (Barc). 2016;52:377-385.
  89. Reddy KR, Roth D, Bruchfeld A, et al. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatol Res. 2017;47:1340-1345.
  90. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the CSURFER study): a combination phase 3 study. Lancet. 2015;386:1537-1545.
  91. Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2:585-594.
  92. Alric L, Ollivier-Hourmand I, Berard E, et al. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. Kidney Int. 2018;94:206-213.
  93. Munoz-Gomez R, Rincon D, Ahumada A, et al. Therapy with ombitasvir/ paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience. J Viral Hepat. 2017;24:464-471.
  94. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590-1598.
  95. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486-504.
  96. Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [Abstract LB-22]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 13-17, 2015. San Francisco, CA; 2015.
  97. Gane EJ, Solà R, Cohen E, et al. RUBY-II: Efficacy and Safety of a Ribavirinfree Ombitasvir/Paritaprevir/Ritonavir _ Dasabuvir Regimen in Patients with Severe Renal Impairment or End-Stage Renal Disease and HCV Genotypes 1a or 4 Infection. Hepatology. 2016;64(Suppl 1):470A.
  98. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCVand severe renal impairment. N Engl J Med. 2017;377:1448-1455.
  99. Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54:677-690. 1
  100. Gane EJ, Robson RA, Bonacini, et al. Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. [Abstract 966]. Hepatology. 2014;60:667A.
  101. Czul F, Schiff E, Peyton C, et al. First ribavirin-free sofosbuvir and simeprevir treatment of Hepatitis C genotype 1 patients with severe renal impairment (GFR №30 ml/min or dialysis). [Abstract P0878]. J Hepatol. 2015;62:S670-S671.
  102. Nazario HE, Ndungu M, Modi A. Safety and efficacy of sofosbuvir + simeprevir without ribavirin in hepatitis C genotype 1-infected patients with end-stage renal disease or GFR №30 ml/min. [Abstract P0802]. J Hepatol. 2015;62:S635.
  103. Perumpail RB, Wong RJ, Pham EA, et al. A new standard of care? standard dose sofosbuvir in an HCV-infected liver transplant recipient undergoing hemodialysis. Dig Dis Sci. 2016;61:39-41.
  104. Perumpail RB, Wong RJ, Ha LD, et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis. 2015;17:275-278.
  105. Desnoyer A, Pospai D, Le MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40-47.
  106. Bhamidimarri KR, Czul F, Peyton A, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63:763-765.
  107. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvircontaining regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-816.
  108. Dumortier J, Bailly F, Pageaux GP, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant. 2017;32:2065-2071.
  109. Li T, Qu Y, Guo Y, et al. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int. 2017;37:974-981.
  110. Gonzalez-Parra E, Soledad PS, et al. Renal function evolution in patients infected with HCV and basal estimated glomerular filtration rate (GFRE) between 30-60 ml/min/1.73 m2 treated with ombitasvir/paritaprevir/ ritonavir and dasabuvir (3D) vs regimens based on sofosbuvir (SOF). EASL Special Conference, September 23-24, 2016. Available at: http:// www.easloffice.eu/office/paris2016/mobile/index.html#p¼172. Accessed February 25, 2018.
  111. Rosenblatt R, Mehta A,Wagner M, Kumar S. Baseline creatinine clearance is a predictor of worsening renal function while on HCV treatment with sofosbuvir-ledipasvir. J Hepatol. 2016;64 Suppl:S819.
  112. Mallet V, Parlati L, Dorval O, et al. Estimated glomerular filtration rate variations and direct acting antivirals treatment for chronic hepatitis C: a retrospective longitudinal study. J Hepatol. 2018;68:S22.
  113. Sise ME, Backman E, Ortiz GA, et al. Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD. Clin J Am Soc Nephrol. 2017;12:1615-1623.
  114. Stark JE, Cole J. Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. Am J Health Syst Pharm. 2017;74:1541-1544.
  115. Lin MV, Sise ME, Pavlakis M, et al. Safety and efficacy of novel antivirals in kidney transplant recipients with chronic hepatitis C virus (HCV) infection. [Abstract LP42]. Journal of Hepatol. 2015;62:S284-S285.
  116. Colombo M, Aghemo A, Liu H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166:109-117.
  117. Fernandez I, Munoz-Gomez R, Pascasio JM, et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol. 2017;66:718-723.
  118. Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvirbased antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16:1474-1479.
  119. Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588-1595.
  120. Agarwal K, Castells L, Mullhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients [e-pub ahead of print]. J Hepatol. https://doi.org/10.1016/j.jhep.2018.05.039. Accessed July 28, 2018.
  121. Morelle J, Goffin E, Wallemacq P, et al. Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended! Transpl Int. 2010;23:1065-1067.
  122. Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant. 2010;10:1238-1246.
  123. Goldberg DS, Abt PL, Blumberg EA, et al. Trial of transplantation of HCVinfected kidneys into uninfected recipients.NEnglJMed. 2017;376:2394-2395.
  124. Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168:533-540.
  125. Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66:13-26.
  126. Mucke MM, Backus LI, Mucke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:172-180.
  127. Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug administration adverse event reporting system. Ann Intern Med. 2017;166:792-798.
  128. Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus infection and kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7:549-557.
  129. Schneeberger PM, Keur I, van Loon AM, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis. 2000;182:1291-1299.
  130. Vladutiu DS, Cosa A, Neamtu A, et al. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat. 2000;7:313-319.
  131. Sun J, Yu R, Zhu B, et al. Hepatitis C infection and related factors in hemodialysis patients in China: systematic review and meta-analysis. Ren Fail. 2009;31:610-620.
  132. Voiculescu M, Iliescu L, Ionescu C, et al. A cross-sectional epidemiological study of HBV, HCV, HDV and HEV prevalence in the SubCarpathian and South-Eastern regions of Romania. J Gastrointestin Liver Dis. 2010;19:43-48.
  133. Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl. 2010;21:1165-1168.
  134. Ali I, Siddique L, Rehman LU, et al. Prevalence of HCVamong the high risk groups in Khyber Pakhtunkhwa. Virol J. 2011;8:296.
  135. Su Y, Norris JL, Zang C, et al. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int. 2013;17:532-541.
  136. Marwaha N, Sachdev S. Current testing strategies for hepatitis C virus infection in blood donors and the way forward. World J Gastroenterol. 2014;20:2948-2954.
  137. Thompson ND, Novak RT, White-Comstock MB, et al. Patient-to-patient hepatitis C virus transmissions associated with infection control breaches in a hemodialysis unit. J Nephrol Therapeutics. 2012;S10:002.
  138. Aho-Glele LS, Giraudon H, Astruc K, et al. Investigation of a case of genotype 5a hepatitis C virus transmission in a french hemodialysis unit using epidemiologic data and deep sequencing. Infect Control Hosp Epidemiol. 2016;37:134-139.
  139. Thompson ND, Novak RT, Datta D, et al. Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique. Infect Control Hosp Epidemiol. 2009;30:900-903.
  140. Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015;38:471-480.
  141. Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904-909.
  142. Centers for Disease Control and Prevention. Healthcare-associated hepatitis B and C outbreaks reported to the Centers for Disease Control and Prevention, 2008-2015. Available at: https://www.cdc.gov/hepatitis/ outbreaks/healthcarehepoutbreaktable.htm. Accessed July 27, 2018.
  143. The Centers for Disease Control and Prevention. CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing hemodialysis. Am J Transplant. 2016;16:1633-1634.
  144. Thompson ND, Perz JF, Moorman AC, et al. Nonhospital health careassociated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med. 2009;150:33-39.
  145. de Lamballerie X, Olmer M, Bouchouareb D, et al. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol. 1996;49:296-302.
  146. McLaughlin KJ, Cameron SO, Good T, et al. Nosocomial transmission of hepatitis C virus within a British dialysis centre. Nephrol Dial Transplant. 1997;12:304-309.
  147. Bieber B, Goodkin DA, Nwankwo C, et al. Hepatitis C prevalence and clinical outcomes in the Dialysis Outcomes and Practice Patterns Study. Neph Dial Transpl. 2015;30 Suppl 3:iii314.
  148. de Jesus Rodrigues de Freitas M, Fecury AA, de Almeida MK, et al. Prevalence of hepatitis C virus infection and genotypes in patient with chronic kidney disease undergoing hemodialysis. J Med Virol. 2013;85:1741-1745.
  149. Santana RR, Martínez Z, Martínez MT, Mato J. Hepatitis C virus present in hemodialysis units from Cuban western region. Rev Cub Meda. 2009;48:28-35.149a.
  150. Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle- East: a systematic review and meta-analysis. World J Gastroenterol. 2017;23:151-166.
  151. Abou Rached A, El Khoury L, El Imad T, et al. Incidence and prevalence of hepatitis B and hepatitis C viruses in hemodialysis patients in Lebanon. World J Nephrol. 2016;5:101-107.
  152. Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis. 2012;12:265.
  153. Ummate I, Denue BA, Kida IM, et al. Risk factors for hepatitis C virus sero-positivity among haemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria. Pan Afr Med.J. 2014;19:305.
  154. Schiller A, Timar R, Siriopol D, et al. Hepatitis B and C virus infection in the hemodialysis population from three romanian regions. Nephron. 2015;129:202-208.
  155. Seck SM, Dahaba M, Gueye S, et al. Trends in hepatitis C infection among hemodialysis patients in Senegal: results of a decade of prevention. Saudi J Kidney Dis Transpl. 2014;25:1341-1345.
  156. Alfurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol. 2000;20:103-106.
  157. Bergervoet PW, van Riessen N, Sebens FW, et al. Application of the forensic Luminol for blood in infection control. J Hosp Infect. 2008;68:329-333.
  158. Caramelo C, de Sequera P, Lopez MD, et al. Hand-borne mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies. Clin Nephrol. 1999;51:59-60.
  159. Froio N, Nicastri E, Comandini UV, et al. Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis. 2003;42:546-550.
  160. Girou E, Chevaliez S, Challine D, et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. Clin Infect Dis. 2008;47:627-633.
  161. Kamili S, Krawczynski K, McCaustland K, et al. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007;28:519-524.
  162. Patel PR, Thompson ND, Kallen AJ, et al. Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients. Am J Kidney Dis. 2010;56:371-378.
  163. Paintsil E, Binka M, Patel A, et al. Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission. J Infect Dis. 2014;209:1205-1211.
  164. Laporte F, Tap G, Jaafar A, et al. Mathematical modeling of hepatitis C virus transmission in hemodialysis. Am J Infect Control. 2009;37:403-407.
  165. Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004-1010.
  166. Shimokura G, Chai F, Weber DJ, et al. Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. Infect Control Hosp Epidemiol. 2011;32:415-424.
  167. Centers for Disease Control and Prevention. Dialysis safety audit tools and checklists. Available at: http://www.cdc.gov/dialysis/prevention-tools/audittools. html. Accessed July 27, 2018.
  168. Labriola L, Jadoul M. The decades-long fight against HBV transmission to dialysis patients: slow but definite progress. Nephrol Dial Transplant. 2010;25:2047-2049.
  169. Jadoul M. Should hemodialysis patients with hepatitis C virus antibodies be isolated? Semin Dial. 1995;8:1-3.
  170. Sypsa V, Psichogiou M, Katsoulidou A, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis. 2005;45:334-343.
  171. Bravo Zuniga JI, Loza Munarriz C, Lopez-Alcalde J. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units. Cochrane Database Syst Rev. 2016:CD006420.
  172. Shamshirsaz AA, Kamgar M, Bekheirnia MR, et al. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol. 2004;5:13.
  173. Karkar A, Abdelrahman M, Ghacha R, et al. Prevention of viral transmission in HD units: the value of isolation. Saudi J Kidney Dis Transpl. 2006;17:183- 188.
  174. Harmankaya O, Cetin B, Erimez D, et al. Patient isolation prevents the transmission of hepatitis C virus infection in hemodialysis units. Dialysis Transpl. 2002;31:859-861.
  175. Dzekova-Vidimliski P, Pavleska-Kuzmanovska S, Trajceska L, et al. Decreasing prevalence of hepatitis C virus infection in hemodialysis patients: Following KDIGO guidelines. Neph Dialysis Transpl. 2012;27(Suppl 2):ii294.
  176. Agarwal SK, Dash SC, Gupta S, et al. Hepatitis C virus infection in haemodialysis: the ’no-isolation’ policy should not be generalized. Nephron Clin Pract. 2009;111:c133-c140.
  177. Gallego E, Lopez A, Perez J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006;104:c1-c6.
  178. Shebeb AM, Kotkat AM, Abd El Reheim SM, et al. An intervention study for prevention of HCV infection in some hemodialysis units in Alexandria. J Egypt Public Health Assoc. 2006;81:119-141.
  179. Yang CS, Chang HH, Chou CC, et al. Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit. J Formos Med Assoc. 2003;102:79-85.
  180. Schvarcz R, Johansson B, Nystrom B, et al. Nosocomial transmission of hepatitis C virus. Infection. 1997;25:74-77.
  181. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int. 1998;53:1022-1025.
  182. Mactier R, Davies S, Dudley C, et al. Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009-2012). Nephron Clin Pract. 2011;118 Suppl 1:c27-c70.
  183. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section VI. Haemodialysis-associated infection. Nephrol Dial Transplant. 2002;17 Suppl 7:72-87.
  184. Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant. 1996;11 Suppl 4:36-38.
  185. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysisassociated diseases in the United States, 2002. Semin Dial. 2005;18:52-61.
  186. dos Santos JP, Loureiro A, Cendoroglo Neto M, et al. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant. 1996;11:2017-2022.
  187. Patel PR, Yi SH, Booth S, et al. Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort: a quality improvement report. Am J Kidney Dis. 2013;62:322-330.
  188. Yi SH, Kallen AJ, Hess S, et al. Sustained infection reduction in outpatient hemodialysis centers participating in a collaborative bloodstream infection prevention effort. Infect Control Hosp Epidemiol. 2016;37:863-866.
  189. Arenas MD, Sanchez-Paya J, Barril G, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant. 2005;20:1164-1171.
  190. Shimokura G, Weber DJ, Miller WC, et al. Factors associated with personal protection equipment use and hand hygiene among hemodialysis staff. Am J Infect Control. 2006;34:100-107.
  191. Ball LK, George CA, Duval L, et al. Reducing blood stream infection in patients on hemodialysis: Incorporating patient engagement into a quality improvement activity. Hemodial Int. 2016;20 Suppl 1:S7-S11.
  192. Sanchez-Carrillo LA, Rodriguez-Lopez JM, Galarza-Delgado DA, et al. Enhancement of hand hygiene compliance among health care workers from a hemodialysis unit using video-monitoring feedback. Am J Infect Control. 2016;44:868-872.
  193. CDC recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep. 2001;50:1-43.
  194. Frieden TR. A framework for public health action: the health impact pyramid. Am J Public Health. 2010;100:590-595.
  195. Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol. 2015;11:172-182.
  196. Fabrizi F, Martin P, Dixit V, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis. 1998;31:647-654.
  197. Pereira BJ, Milford EL, Kirkman RL, et al. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991;325:454-460.
  198. Kamar N, Ribes D, Izopet J, et al. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant. Transplantation. 2006;82:853-856.
  199. Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis. 1997;29:608-614.
  200. Stehman-Breen CO, Emerson S, Gretch D, et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32:629-634.
  201. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 1998;65:667-670.
  202. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257-263.
  203. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renalreplacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78:745-750.
  204. Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.
  205. Scott DR, Wong JK, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90:1165-1171.
  206. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270:1339-1343.
  207. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725-1730.
  208. Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53:1374-1381.
  209. Bloom RD, Sayer G, Fa K, et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5:139-144.
  210. Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003;14:2092-2098.
  211. Nicot F, Kamar N, Mariame B, et al. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int. 2010;23:594-601.
  212. Cruzado JM, Casanovas-Taltavull T, Torras J, et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant. 2003;3:357-360.
  213. Forman JP, Tolkoff-Rubin N, Pascual M, et al. Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol. 2004;15:3249-3255.
  214. Alric L, Di-Martino V, Selves J, et al. Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology. 2002;123:1494-1499.
  215. Fehr T, Riehle HM, Nigg L, et al. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis. 2003;42:193-201.
  216. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virusrelated liver fibrosis after renal transplantation. Am J Transplant. 2005;5:1704-1712.
  217. Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22:1152-1160.
  218. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol. 2004;35:107-112.
  219. Eason JD, Gonwa TA, Davis CL, et al. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant. 2008;8:2243-2251.
  220. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488.
  221. Rostaing L, Izopet J, Baron E, et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995;59:1426-1431.
  222. Chascsa DM, Mousa OY, Pungpapong S, et al. Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: a multi-center study [e-pub ahead of print]. Am J Transplant. https://doi.org/10.1111/ajt.14931.
  223. Diethelm AG, Roth D, Ferguson RM, et al. Transmission of HCV by organ transplantation. N Engl J Med. 1992;326:410-411.
  224. European Best Practice Guidelines for Renal Transplantation. Section I: Evaluation, selection and preparation of the potential recipient. Nephrol Dial Transplant. 2000;15(suppl 7):3-38.
  225. Nowak KM, Witzke O, Sotiropoulos GC, et al. Transplantation of renal allografts from organ donors reactive for HCV antibodies to HCVnegative recipients: safety and clinical outcome. Kidney Int Rep. 2016;2:53-59.
  226. Wolfe CR, Michaels MG. Donor-derived hepatitis C transmission from NAT negative donors-Still an unexpected event! Am J Transplant. 2017;17:2989.
  227. Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17:2790- 2802.
  228. Kling CE, Perkins JD, Landis CS, et al. Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: time for change. Am J Transplant. 2017;17:2863-2868.
  229. Morales JM, Andres A, Campistol JM. Hepatitis C virus and organ transplantation. N Engl J Med. 1993;328:511-512.
  230. Morales JM, Campistol JM, Castellano G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pretransplantation anti-HCV. Kidney Int. 1995;47:236-240.
  231. Abbott KC, Lentine KL, Bucci JR, et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed longterm dialysis patients. Am J Transplant. 2004;4:2032-2037.
  232. Ali MK, Light JA, Barhyte DY, et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation. 1998;66:1694-1697.
  233. Bucci JR, Lentine KL, Agodoa LY, et al. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl. 2004:51-61.
  234. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol. 2002;13:2974-2982.
  235. Maluf DG, Archer KJ, Mas VR. Kidney grafts from HCV-positive donors: advantages and disadvantages. Transplant Proc. 2010;42:2436-2446.
  236. Mandal AK, Kraus ES, Samaniego M, et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant. 2000;14:391-396.
  237. Singh N, Neidlinger N, Djamali A, et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant. 2012;26:684-693.
  238. Morales JM, Campistol JM, Dominguez-Gil B, et al. Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant. 2010;10:2453-2462.
  239. Jawa P, Knorr J, Torres E, et al. Donor hepatitis C status does not impact outcomes in hepatitis C positive kidney transplant recipients [abstract]. Am J Transplant. 2013;13(suppl 5):403.
  240. Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015;99:1192-1196.
  241. Myint T, Wright A, Rose C, et al. The benefit of hepatitis C donor kidney transplantation is limited to hepatitis C positive patients over 50 years of age [abstract]. Am J Transplant. 2015;15(suppl 3). Available at: https:// atcmeetingabstracts.com/abstract/the-benefit-of-hepatitis-c-donor-kidneytransplantation- is-limited-to-hepatitis-c-positive-patients-over-50-years-ofage/. Accessed July 27, 2018.
  242. Bhamidimarri KR, Ladino M, Pedraza F, et al. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a singlecenter retrospective study. Transpl Int. 2017;30:865-873.
  243. Widell A, Mansson S, Persson NH, et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCVinfected kidney. Transplantation. 1995;60:642-647.
  244. Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease. J Am Soc Nephrol. 2016;27:2238-2246.
  245. Sawinski D, Bloom RD. Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation. 2015;99:2458-2466.
  246. Limkemann A, Ramanathan R, Benhke M, et al. Inferior outcomes in hepatitis C virus positive donors to hepatitis C virus negative kidney recipients: analysis from National data 2015 [abstract]. Am J Transplant. 2015;suppl 1:76.
  247. Reese PP, Abt PL, Blumberg EA, et al. Transplanting hepatitis C-positive kidneys. N Engl J Med. 2015;373:303-305.
  248. Cortijo C. Impacto de la terapia de induccion con agents biologicos en los resultados del trasplante renal en pacientes con infeccion por le virus de la hepatitis C. Doctoral Thesis, Universidad Europea de Madrid, Madrid (Spain) 2012.
  249. Sureshkumar KK, Hussein SM, Thai NI, Marcus RJ. Kidney transplant outcomes in African American patients with hepatitis C: influence of induction agent [abstract]. Am J Transplant. 2012;suppl 3:320.
  250. Linatoc Q, Ren M, Behnke, et al. Effect of induction therapy with thymoglobulin on outcome in hepatitis C infected kidney transplant recipients: a single center experience [abstract]. Am J Transplant. 2013;suppl 3:85.
  251. Luan FL, Schaubel DE, Zhang H, et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation. 2008;85:1601-1606.
  252. Manuel O, Baid-Agrawal S, Moradpour D, et al. Immunosuppression in hepatitis C virus-infected patients after kidney transplantation. Contrib Nephrol. 2012;176:97-107.
  253. Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13:1374-1380.
  254. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology. 2003;38:1282-1288.
  255. Rostaing L, Izopet J, Sandres K, et al. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation. 2000;69:991-994.
  256. Gentil Govantes MA, Esforzado N, Cruzado JM, et al. Harmful effects of viral replication in seropositive hepatitis C virus renal transplant recipients. Transplantation. 2012;94:1131-1137.
  257. Hestin D, Guillemin F, Castin N, et al. Pretransplant hepatitis C virus infection: a predictor of proteinuria after renal transplantation. Transplantation. 1998;65:741-744.
  258. Cruzado JM, Gil-Vernet S, Ercilla G, et al. Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol. 1996;7:2469-2475.
  259. Morales JM, Pascual-Capdevila J, Campistol JM, et al. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63:1634-1639.
  260. Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol. 1999;10:146-153.
  261. Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14:2206-2220.
  262. Bonacci M, Lens S, Londono MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15:575-583.
  263. Gragnani L, Piluso A, Urraro T, et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets. 2017;18:772-785.
  264. Gragnani L, Visentini M, Fognani E, et al. Prospective study of guidelinetailored therapy with direct-acting antivirals for hepatitis C virusassociated mixed cryoglobulinemia. Hepatology. 2016;64:1473-1482.
  265. Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75:1777-1782.
  266. Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virusassociated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408-417.
  267. Cacoub P, Vautier M, Desbois AC, et al. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era. Liver Int. 2017;37:1805-1813.
  268. Emery JS, Kuczynski M, La D, et al. Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia. Am J Gastroenterol. 2017;112:1298-1308.
  269. Lauletta G, Russi S, Pavone F, et al. Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a singlecentre experience. Arthritis Res Ther. 2017;19:74.
  270. Mazzaro C, Dal Maso L, Quartuccio L, et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol. 2018;36 Suppl 111:107-114.
  271. Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 2017;153:49-52.
  272. Gill K, Ghazinian H, Manch R, et al. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415-423.
  273. Kasuno K, Ono T, Matsumori A, et al. Hepatitis C virus-associated tubulointerstitial injury. Am J Kidney Dis. 2003;41:767-775.
  274. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490-1495.
  275. Fabrizi F, Colucci P, Ponticelli C, et al. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol. 2002;22:309-318.
  276. Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61:623-637.
  277. Ferri C, Greco F, Longombardo G, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991;34:1606-1610.
  278. Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis. 2008;12:611-636.
  279. Arase Y, Ikeda K, Murashima N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med. 1998;37:836-840.
  280. El-Serag HB, Hampel H, Yeh C, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439-1445.
  281. Kristiansen MG, Gutteberg TJ, Mortensen L, et al. Clinical outcomes in a prospective study of community-acquired hepatitis C virus infection in Northern Norway. Scand J Gastroenterol. 2010;45:746-751.
  282. Fabrizi F, Pozzi C, Farina M, et al. Hepatitis C virus infection and acute or chronic glomerulonephritis: an epidemiological and clinical appraisal. Nephrol Dial Transplant. 1998;13:1991-1997.
  283. Huang JF, Chuang WL, Dai CY, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med. 2006;260:255-262.
  284. Ishizaka N, Ishizaka Y, Seki G, et al. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res. 2008;38:775-783.
  285. Lee JJ, Lin MY, Yang YH, et al. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010;56:23-31.
  286. Yanik EL, Lucas GM, Vlahov D, et al. HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol. 2010;5:1836-1843.
  287. Ando M, Yanagisawa N, Ajisawa A, et al. Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant. 2011;26:3923-3929.
  288. Banerjee T, Scherzer R, Powe NR, et al. Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans. J Acquir Immune Defic Syndr. 2014;67:145-152.
  289. Estrella MM, Wyatt CM, Pearce CL, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int. 2013;84:834-840.
  290. Reynes J, Cournil A, Peyriere H, et al. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate >/¼ 60 ml/ min per 1.73 m2. AIDS. 2013;27:1295-1302.
  291. Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195- 202.
  292. Yanagisawa N, Ando M, Ajisawa A, et al. Clinical characteristics of kidney disease in Japanese HIV-infected patients. Nephron Clin Pract. 2011;118: c285-c291.
  293. Morales JM, Morales E, Andres A, et al. Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens. 1999;8:205-211.
  294. Meyers CM, Seeff LB, Stehman-Breen CO, et al. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631-657.
  295. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139-274.
  296. Kupin WL. Viral-Associated GN: Hepatitis C and HIV. Clin J Am Soc Nephrol. 2017;12:1337-1342.
  297. D’Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int. 1998;54:650-671.
  298. Stehman-Breen C, Alpers CE, Fleet WP, et al. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron. 1999;81:37-40.
  299. Dey AK, Bhattacharya A, Majumdar A. Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol. 2013;23:143-145.
  300. Usalan C, Erdem Y, Altun B, et al. Rapidly progressive glomerulonephritis associated with hepatitis C virus infection. Clin Nephrol. 1998;49:129-131.
  301. Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol. 1998;9:2244-2252.
  302. Barsoum RS. Hepatitis C virus: from entry to renal injury-facts and potentials. Nephrol Dial Transplant. 2007;22:1840-1848.
  303. Wornle M, Schmid H, Banas B, et al. Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol. 2006;168:370-385.
  304. Sansonno D, Gesualdo L, Manno C, et al. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology. 1997;25:1237-1244.
  305. Sansonno D, Lauletta G, Montrone M, et al. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol. 2005;140:498-506.
  306. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int. 1994;46:1700-1704.
  307. Mazzaro C, Panarello G, Mauro E, et al. Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis. Dig Liver Dis. 2015;47:613-616.
  308. Mazzaro C, Monti G, Saccardo F, et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clin Exp Rheumatol. 2011;29:933-941.
  309. Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a longterm followup study. Arthritis Rheum. 2006;54:3696-3706.
  310. Fabrizi F, Bruchfeld A, Mangano S, et al. Interferon therapy for HCVassociated glomerulonephritis: meta-analysis of controlled trials. Int J Artif Organs. 2007;30:212-219.
  311. Fabrizi F, Martin P, Cacoub P, et al. Treatment of hepatitis C-related kidney disease. Expert Opin Pharmacother. 2015;16:1815-1827.
  312. De Nicola S, Aghemo A, Campise MR, et al. Telaprevir in a patient with chronic hepatitis C and cryoglobulinemic glomerulonephritis. Antivir Ther. 2014;19:527-531.
  313. Ennaifer R, Sabbah M, Hefaiedh R, et al. Antiviral therapy for hepatitis C virus infection, cryoglobulinemic glomerulonephritis and low-grade malignant lymphoma: A challenge? Tunis Med. 2015;93:203-204.
  314. Iliescu L, Herlea V, Toma L, et al. Association between chronic HCV hepatitis, membranoproliferative glomerulopathy and cutaneous sarcoidosis. J Gastrointestin Liver Dis. 2015;24:8.
  315. Mauro E, Gattei V, Mazzaro C. Recombinant human erythropoietin (RHuEpo) and granular colony stimulating factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description. Infez Med. 2014;22:337-341.
  316. Otsuka T, Sakai Y, Ohno D, et al. A case of cryoglobulinemic membranoproliferative glomerulonephritis induced by hepatitis C virus. J Nippon Med Sch. 2015;82:193-201.
  317. Wu H, Zou HB, Xu Y, et al. Hepatitis C virus-related heat-insoluble cryoglobulinemia and thrombotic microangiopathy. Am J Med Sci. 2013;346:345-348.
  318. Zhao LJ, Chen F, Li JG, et al. Hepatitis C virus-related mixed cryoglobulinemic endocapillary proliferative glomerulonephritis and B-cell non-Hodgkin lymphoma: a case report and literature review. Eur Rev Med Pharmacol Sci. 2015;19:3050-3055.
  319. Dussol B, Moal V, Daniel L, et al. Spontaneous remission of HCV-induced cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2001;16:156-159.
  320. Davis CL, Gretch DR, Perkins JD, et al. Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transpl Surg. 1995;1:166-175.
  321. Donato MF, Fabrizi F, Fogazzi GB, et al. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review. Int J Artif Organs. 2013;36:63-68.
  322. Francesca Donato M, Banfi G, Cresseri D, et al. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review. Int J Artif Organs. 2013;36:367-372.
  323. Montalbano M, Pasulo L, Sonzogni A, et al. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol. 2007;41:216-220.
  324. Fabrizi F, Aghemo A, Fogazzi GB, et al. Acute tubular necrosis following interferon-based therapy for hepatitis C: case study with literature review. Kidney Blood Press Res. 2013;38:52-60.
  325. Artemova M, Abdurakhmanov D, Ignatova T, et al. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology. 2017;65:1770-1771.
  326. Cornella SL, Stine JG, Kelly V, et al. Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including directacting antiviral sofosbuvir: A case series. Postgrad Med. 2015;127:413-417.
  327. Sollima S, Milazzo L, Peri AM, et al. Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy. Rheumatology (Oxford). 2016;55:2084-2085.
  328. Cacoub P, Si Ahmed SN, Ferfar Y, et al. Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis [e-pub ahead of print]. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2018.05.021.
  329. Bonacci M, Lens S, Marino Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure [e-pub ahead of print]. Gastroenterology. 2018;155:311-315.
  330. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33:355-374.
  331. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47:618-623.
  332. Tarantino A, De Vecchi A, Montagnino G, et al. Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients. Q J Med. 1981;50:1-30.
  333. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008;3:25.
  334. Ahmed MS, Wong CF, Shawki H, et al. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature. Clin Nephrol. 2008;69:298-301.
  335. Palombo SB, Wendel EC, Kidd LR, et al. MPGN and mixed cryoglobulinemia in a patient with hepatitis C - new treatment implications and renal outcomes. Clin Nephrol Case Stud. 2017;5:66-69.
  336. Humphries K, Darling JM, Barritt ASt. Membranoproliferative glomerulonephritis, type II cryoglobulinemia and triple therapy for hepatitis C: a case series and review of the literature. Dig Dis Sci. 2014;59:2007-2012.
  337. Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol. 2008;34:111-117.
  338. Roccatello D, Sciascia S, Baldovino S, et al. Improved (4 plus 2) rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study. Am J Nephrol. 2016;43:251-260.
  339. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferonalpha/ ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116:326-334.
  340. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843-853.
  341. Quartuccio L, Zuliani F, Corazza L, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. J Autoimmun. 2015;63:88-93.
  342. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835-842.
  343. Fabrizi F,Martin P, ElliA, et al.HepatitisCvirus infection and rituximab therapy after renal transplantation. Int J Artif Organs. 2007;30:445-449.
  344. US Food and Drug Administration. FDA Drug Safety Communication: Boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab). Available at: https://www.fda. gov/drugs/drugsafety/ucm366406.htm. Accessed March 23, 2018.
  345. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62:1787-1795.
  346. Colucci G, Manno C, Grandaliano G, et al. Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. Clin Nephrol. 2011;75:374-379.
  347. Reed MJ, Alexander GJ, Thiru S, et al. Hepatitis C-associated glomerulonephritis-a novel therapeutic approach. Nephrol Dial Transplant. 2001;16:869-871.
  348. Castillo I, Martinez-Ara J, Olea T, et al. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Kidney Int. 2014;86:619-624.
  349. IOM (Institute of Medicine). Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press; 2011.
  350. IOM (Institute of Medicine). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The National Academies Press; 2011.
  351. Prabhu RA, Nair S, Pai G, et al. Interventions for dialysis patients with hepatitis C virus (HCV) infection. Cochrane Database Syst Rev. 2015: CD007003.
  352. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
  353. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford. asp. Accessed July 27, 2018.
  354. Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058-2065.
  355. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ. 2008;336:1049-1051.
  356. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
  357. Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139:493-498.

Другие статьи по теме


Навигация по статьям
Разделы журнала
Наиболее читаемые статьи
Журнал "Нефрология и диализ"